- Genitourinary Cancer
  - Urothelial tract/bladder cancer
    - Urothelial cancer
      - ***10636:** Phase 1 Trial of CA-4948 in Combination with Pembrolizumab to Overcome Resistance to PD-1/PD-L1 Blockade in Metastatic Urothelial Cancer
      - **10483:** Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations
    - Urothelial carcinoma with DNA-repair defects
      - **10144:** A Phase II Study of Olaparib (AZD2281) in Patients with Metastatic/Advanced Urothelial Carcinoma and other genitourinary tumors with DNA-Repair Defects
  - Prostate cancer
    - Castration-resistant prostate cancer
      - **10096:** A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE)
      - **10301:** A Phase I and Randomized Phase II Trial of Radium-223 Dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    - Metastatic prostate cancer
      - **10487:** A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer with Neuroendocrine Differentiation
    - SPOP-Mutant prostate cancer
      - **10603:** Phase II Study of M1774 in Refractory SPOP-Mutant Prostate Cancer
  - Renal cell carcinoma
    - Papillary renal cell carcinoma
      - **▼ 10466:** A Phase II Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April 24, 2024